Shareholders to Vote on Reverse Stock Split to Maintain Nasdaq Listing and Enable Future Capital Raises

summarizeSummary

Cytosorbents has filed its definitive proxy statement, setting the stage for an August 13, 2026, shareholder vote on a reverse stock split, a critical measure to maintain its Nasdaq listing and facilitate future financing amidst ongoing financial challenges.

check_boxKey Events

• Shareholder Meeting Scheduled

  The Annual Meeting of Stockholders is scheduled for August 13, 2026, to vote on several key proposals.

• Reverse Stock Split Proposal

  Shareholders will vote on an amendment to the Certificate of Incorporation to effect a reverse stock split with a ratio between 1-for-5 and 1-for-20, at the Board's discretion.

• Purpose: Maintain Nasdaq Listing

  The primary goal of the reverse stock split is to increase the per-share price to meet Nasdaq's $1.00 minimum bid price requirement and avoid delisting, following a 180-day extension granted on April 1, 2026.

• Facilitate Future Capital Raising

  The company believes the reverse split will make its common stock more attractive to institutional investors and better enable future financing to fund ongoing operations.

auto_awesomeAnalysis

This definitive proxy statement confirms the upcoming shareholder meeting on August 13, 2026, where a critical vote on a reverse stock split will take place. The proposal, ranging from 1-for-5 to 1-for-20, is a direct response to the company's failure to meet Nasdaq's minimum $1.00 bid price requirement, as highlighted by previous regulatory notices and a going concern warning. Approval is essential to avoid delisting and is also intended to make the stock more attractive for future capital-raising efforts, which are crucial given the company's liquidity challenges and deferred executive bonuses.